Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Consensus Recommendation of "Buy" from Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) has received an average recommendation of "Buy" from the six brokerages that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $25.83.

A number of brokerages recently issued reports on CNTA. BMO Capital Markets increased their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an "outperform" rating in a research report on Monday, September 16th. B. Riley started coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a "buy" rating and a $33.00 price objective for the company. Guggenheim boosted their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a "buy" rating in a report on Friday, November 15th. Morgan Stanley raised Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $11.00 to $26.00 in a report on Thursday, September 19th. Finally, Jefferies Financial Group increased their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th.

Insider Activity

In related news, CEO Saurabh Saha sold 87,496 shares of the business's stock in a transaction on Friday, December 6th. The shares were sold at an average price of $18.46, for a total value of $1,615,176.16. Following the sale, the chief executive officer now directly owns 575,661 shares of the company's stock, valued at approximately $10,626,702.06. The trade was a 13.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $17.04, for a total value of $170,400.00. Following the transaction, the insider now directly owns 183,266 shares of the company's stock, valued at $3,122,852.64. This represents a 5.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 368,023 shares of company stock valued at $6,335,574 in the last 90 days. 11.59% of the stock is owned by company insiders.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its stake in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock valued at $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock worth $48,000 after purchasing an additional 1,509 shares during the last quarter. Quarry LP raised its holdings in shares of Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company's stock valued at $87,000 after purchasing an additional 3,108 shares during the period. Sandia Investment Management LP acquired a new stake in Centessa Pharmaceuticals in the 2nd quarter valued at about $90,000. Finally, Fred Alger Management LLC bought a new stake in Centessa Pharmaceuticals in the second quarter valued at approximately $99,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock traded down $0.31 on Friday, hitting $16.95. The company's stock had a trading volume of 262,653 shares, compared to its average volume of 431,983. Centessa Pharmaceuticals has a one year low of $6.65 and a one year high of $18.97. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market cap of $2.23 billion, a P/E ratio of -11.08 and a beta of 1.52. The company has a fifty day moving average price of $16.73 and a 200-day moving average price of $13.89.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. On average, equities analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.